|
1
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thibault B, Castells M, Delord JP and
Couderc B: Ovarian cancer microenvironment: Implications for cancer
dissemination and chemoresistance acquisition. Cancer Metastasis
Rev. 33:17–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nieman KM, Kenny HA, Penicka CV, Ladanyi
A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB,
Hotamisligil GS, et al: Adipocytes promote ovarian cancer
metastasis and provide energy for rapid tumor growth. Nat Med.
17:1498–1503. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bapat SA, Mali AM, Koppikar CB and Kurrey
NK: Stem and progenitor-like cells contribute to the aggressive
behavior of human epithelial ovarian cancer. Cancer Res.
65:3025–3029. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alvero AB, Chen R, Fu HH, Montagna M,
Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M,
Visintin I and Mor G: Molecular phenotyping of human ovarian cancer
stem cells unravels the mechanisms for repair and chemoresistance.
Cell Cycle. 8:158–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.PubMed/NCBI
|
|
7
|
Zack TI, Schumacher SE, Carter SL,
Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhsng CZ, Wala J,
Mermel CH, et al: Pan-cancer patterns of somatic copy number
alteration. Nat Genet. 45:1134–1140. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patch AM, Christie EL, Etemadmoghadam D,
Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey
PJ, et al: Whole-genome characterization of chemoresistant ovarian
cancer. Nature. 521:489–494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Malek JA, Mery E, Mahmoud YA, Al-Azwani
EK, Roger L, Huang R, Jouve E, Lis R, Thiery JP, Querleu D and
Rafii A: Copy number variation analysis of matched ovarian primary
tumors and peritoneal metastasis. PLoS One. 6:e285612011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bracken CP, Scott HS and Goodall GJ: A
network-biology perspective of microRNA function and dysfunction in
cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Connell RM, Rao DS and Baltimore D:
microRNA regulation of inflammatory responses. Annu Rev Immunol.
30:295–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deb B, Uddin A and Chakraborty S: miRNAs
and ovarian cancer: An overview. J Cell Physiol. 233:3846–3854.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mihanfar A, Fattahi A and Nejabati HR:
MicroRNA-mediated drug resistance in ovarian cancer. J Cell
Physiol. Jun 19–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Palma Flores C, García-Vázquez R, Gallardo
Rincón D, Ruiz-García E, Astudillo de la Vega H, Marchat LA,
Salinas Vera YM and López-Camarillo C: MicroRNAs driving invasion
and metastasis in ovarian cancer: Opportunities for translational
medicine (Review). Int J Oncol. 50:1461–1476. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raposo G and Stoorvogel W: Extracellular
vesicles: Exosomes, microvesicles, and friends. J Cell Biol.
200:373–383. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X and Wang X: The emerging roles and
therapeutic potential of exosomes in epithelial ovarian cancer. Mol
Cancer. 16:922017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakamura K, Sawada K, Kinose Y, Yoshimura
A, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Morishige KI,
Kurachi H, et al: Exosomes promote ovarian cancer cell invasion
through transfer of CD44 to peritoneal mesothelial cells. Mol
Cancer Res. 15:78–92. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang MK and Wong AS: Exosomes: Emerging
biomarkers and targets for ovarian cancer. Cancer Lett. 367:26–33.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Armstrong RN, Colyer HA and Mills KI:
Screening for miRNA expression changes using quantitative PCR
(Q-PCR). Methods Mol Biol. 863:293–302. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Azaïs H, Estevez JP, Foucher P, Kerbage Y,
Mordon S and Collinet P: Dealing with microscopic peritoneal
metastases of epithelial ovarian cancer. A surgical challenge. Surg
Oncol. 26:46–52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa
M, Ikeda SI, Kato T, Kiyono T, Takeshita F, Kajiyama H, Kikkawa F
and Ochiya T: Malignant extracellular vesicles carrying MMP1 mRNA
facilitate peritoneal dissemination in ovarian cancer. Nature
Commun. 8:144702017. View Article : Google Scholar
|
|
23
|
Keller S, König AK, Marmé F, Runz S,
Wolterink S, Koensgen D, Mustea A, Sehouli J and Altevogt P:
Systemic presence and tumor-growth promoting effect of ovarian
carcinoma released exosomes. Cancer Lett. 278:73–81. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Z, Chen JQ, Liu JL and Tian L:
Exosomes in tumor microenvironment: Novel transporters and
biomarkers. J Transl Med. 14:2972016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kumar D, Gupta D, Shankar S and Srivastava
RK: Biomolecular characterization of exosomes released from cancer
stem cells: Possible implications for biomarker and treatment of
cancer. Oncotarget. 6:3280–3291. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vaksman O, Stavnes HT, Kaern J, Trope CG,
Davidson B and Reich R: miRNA profiling along tumour progression in
ovarian carcinoma. J Cell Mol Med. 15:1593–1602. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cao D, Jia Z, You L, Wu Y, Hou Z, Suo Y,
Zhang H, Wen S, Tsukamoto T, Oshima M, et al: 18β-glycyrrhetinic
acid suppresses gastric cancer by activation of miR-149-3p-Wnt-1
signaling. Oncotarget. 7:71960–71973. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okato A, Arai T, Yamada Y, Sugawara S,
Koshizuka K, Fujimura L, Kurozumi A, Kato M, Kojima S, Naya Y, et
al: Dual strands of pre-miR-149 inhibit cancer cell migration and
invasion through targeting FOXM1 in renal cell carcinoma. Int J Mol
Sci. 18(pii): E19692017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Si L, Xu L, Yin L, Qi Y, Han X, Xu Y, Zhao
Y, Liu K and Peng J: Potent effects of dioscin against pancreatic
cancer via miR-149-3P-mediated inhibition of the Akt1 signalling
pathway. Br J Pharmacol. 174:553–568. 2017. View Article : Google Scholar : PubMed/NCBI
|
